Clinical trial · Interventional
A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma
A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma
NCT01677390CI-TRIAL-00013582terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety of SGN-75 in combination with everolimus in patients with CD70-positive metastatic renal cell carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| everolimus | Drug | Everolimus | ALIAS |
| SGN-75 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm 1
- description
- SGN-75, everolimus
- interventionNames
- Drug: SGN-75
- Drug: everolimus
Primary outcomes (1)
- measure
- Incidence of adverse events and laboratory abnormalities
- timeFrame
- Through 1 month post last dose
Secondary outcomes (5)
- measure
- Best clinical response according to RECIST Version 1.1
- timeFrame
- Through 1 month post last dose
- measure
- Progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of metastatic renal cell carcinoma with confirmed CD70 expression * Previously treated with at least 1 tyrosine kinase inhibitor (TKI) * Measurable disease * Eastern Cooperative Oncology Group performance status 0 or 1 * Adequate lung and renal function Exclusion Criteria: * Prior treatment with anti-CD70-directed therapy * Received more than one prior treatment with an mTOR inhibitor
References
Publications (0)
Data not yet available
No reference posted for this study.